Abstract
Heart rate is a major determinant of cardiac output and myocardial oxygen utilization and is increasingly being nominated as a modifiable risk factor for cardiovascular disease. Despite this evidence, screening strategies for preventing cardiovascular diseases do not include routine assessment of resting heart rate. Reasonably, heart rate reduction has been suggested as a useful approach against angina pectoris in subjects with acute or chronic coronary syndromes. Accordingly, reduction of heart rate in patients with stable angina could be an additional goal of therapy. Important data have shown retrospectively the beneficial effect of heart rate-lowering drugs, such as betaadrenoceptor antagonists, non-dihydropyridine calcium channel antagonists, as well as other agents, on several parameters in patients with coronary artery disease and stable angina. However, additional data are now being sought to assess the impact of this approach on clinical practice.
Keywords: Stable angina, heart rate, therapeutic target, beta-blockers, ivabradine, ranolazine, cardiac output, myocardial oxygen, cardiovascular diseases, non-dihydropyridine calcium channel
Current Pharmaceutical Design
Title:Heart Rate as a Therapeutic Target in Angina Pectoris
Volume: 19 Issue: 9
Author(s): Emmanuel Androulakis, Dimitris Tousoulis, Nikolaos Papageorgiou, Anna Kontogeorgou, Alexandros Briasoulis, Marietta Charakida, Gerasimos Siasos, Evangelos Oikonomou, Katerina Siama, George Latsios and Christodoulos Stefanadis
Affiliation:
Keywords: Stable angina, heart rate, therapeutic target, beta-blockers, ivabradine, ranolazine, cardiac output, myocardial oxygen, cardiovascular diseases, non-dihydropyridine calcium channel
Abstract: Heart rate is a major determinant of cardiac output and myocardial oxygen utilization and is increasingly being nominated as a modifiable risk factor for cardiovascular disease. Despite this evidence, screening strategies for preventing cardiovascular diseases do not include routine assessment of resting heart rate. Reasonably, heart rate reduction has been suggested as a useful approach against angina pectoris in subjects with acute or chronic coronary syndromes. Accordingly, reduction of heart rate in patients with stable angina could be an additional goal of therapy. Important data have shown retrospectively the beneficial effect of heart rate-lowering drugs, such as betaadrenoceptor antagonists, non-dihydropyridine calcium channel antagonists, as well as other agents, on several parameters in patients with coronary artery disease and stable angina. However, additional data are now being sought to assess the impact of this approach on clinical practice.
Export Options
About this article
Cite this article as:
Androulakis Emmanuel, Tousoulis Dimitris, Papageorgiou Nikolaos, Kontogeorgou Anna, Briasoulis Alexandros, Charakida Marietta, Siasos Gerasimos, Oikonomou Evangelos, Siama Katerina, Latsios George and Stefanadis Christodoulos, Heart Rate as a Therapeutic Target in Angina Pectoris, Current Pharmaceutical Design 2013; 19 (9) . https://dx.doi.org/10.2174/1381612811319090003
DOI https://dx.doi.org/10.2174/1381612811319090003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Random Walks on Biomedical Networks
Current Proteomics Leptinaemia and Antiendothelial Antibodies in Accelerated Atherosclerosis – Is There a Relationship?
Vascular Disease Prevention (Discontinued) Sepsis: Links between Pathogen Sensing and Organ Damage
Current Pharmaceutical Design Synergy of microRNA and Stem Cell: A Novel Therapeutic Approach for Diabetes Mellitus and Cardiovascular Diseases
Current Diabetes Reviews Drug-Loaded Nanocarriers in Tumor Targeted Drug Delivery
Current Biotechnology Cytokinin Nucleosides - Natural Compounds with a Unique Spectrum of Biological Activities
Current Topics in Medicinal Chemistry Evaluation and Exploitation of Bioactive Compounds of Walnut, Juglans regia
Current Pharmaceutical Design Smoking and Hypertension: Effects on Clinical, Biochemical and Pathological Variables Due to Isolated or Combined Action on Cardiovascular System
Current Pharmaceutical Design Radiolabelled Quinoline Derivaties for the PET Imaging of Peripheral Benzodiazepine Receptor
Current Medical Imaging Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Omega-3 Fatty Acids: from Biochemistry to their Clinical Use in the Prevention of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery Radial Distribution of Elasticity in Porcine Thoracic Aorta
Vascular Disease Prevention (Discontinued) Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer- Related Anorexia/Cachexia
Current Nutrition & Food Science Illuminating microRNA Transcription from the Epigenome
Current Genomics Vascular Disease and Risk Factors in Chronic Kidney Disease
Vascular Disease Prevention (Discontinued) The Emerging Role of Coenzyme Q-10 in Aging, Neurodegeneration, Cardiovascular Disease, Cancer and Diabetes Mellitus
Current Neurovascular Research Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Liver X Receptors: Potential Novel Targets in Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Microwave-Assisted Synthesis of Benzo-fused Seven-membered Azaheterocycles
Mini-Reviews in Organic Chemistry